Axsome Therapeutics Inc

Contract, Commercial Operations

United States

Not SpecifiedCompensation
Mid-level (3 to 4 years)Experience Level
Full TimeJob Type
UnknownVisa
BiopharmaceuticalIndustries

Requirements

Candidates must possess a Bachelor's degree in a related business or scientific discipline and have a minimum of 5 years of experience with Veeva CRM, data stewardship, and claims/specialty pharmacy data management, including managing ZTT/Roster/Target lists. Additionally, a minimum of 3 years of experience in Integrated Change (IC) and territory alignment design is required, along with proficiency in Microsoft Office. Experience designing and building visualizations using PowerBI or similar business intelligence tools is essential, as is a strong interest in learning new tools and software. Demonstrated expertise in analytical methodologies, statistics, and implementing structured approaches to analyzing business problems is also necessary.

Responsibilities

The Contract, Commercial Operations professional will integrate and manage new data sets, including claims and payer data, to support product launches. Key duties include ensuring data quality and validation, enhancing CRM functionality, and coordinating process improvements. This role involves managing cross-functional collaboration, performing data analysis, and maintaining documentation for accurate reporting solutions. Responsibilities also include managing team rosters, assessing alignment changes, communicating key inputs to cross-functional partners, and assisting in planning integrated change request processes. The incumbent will build geographical sales analyses, analyze data requirements for reporting solutions, and create and maintain SOP documentation for business operations solutions, data mapping, data dictionaries, and reporting standards. They will also ensure adherence to relevant regulatory requirements and company SOPs.

Skills

Data Quality
Data Validation
CRM
Veeva CRM
Process Improvement
Cross-functional Collaboration
Data Analysis
Documentation
Reporting
Sales Analysis
SOPs
Data Mapping
Data Dictionaries

Axsome Therapeutics Inc

Develops therapies for CNS disorders

About Axsome Therapeutics Inc

Axsome Therapeutics develops therapies for central nervous system (CNS) disorders, focusing on conditions like major depressive disorder, treatment-resistant depression, and Alzheimer's agitation. Their main product, AXS-05, is an oral medication that works by blocking NMDA receptors in the brain, which helps regulate mood. This drug has shown positive results in clinical trials and has received special FDA status to speed up its approval process. Unlike many competitors, Axsome emphasizes addressing unmet medical needs in CNS disorders and aims to improve patient outcomes through rigorous research and development. The company's goal is to bring effective treatments to market, enhancing the quality of life for patients suffering from these conditions.

New York City, New YorkHeadquarters
2012Year Founded
$430.7MTotal Funding
IPOCompany Stage
Biotechnology, HealthcareIndustries
201-500Employees

Benefits

Performance Bonus
Company Equity

Risks

Increased competition from companies like Compass Pathways in the CNS market.
Potential delays in AXS-07 launch amid growing market anticipation.
Departure of key personnel like Lori Englebert may impact strategic direction.

Differentiation

Axsome focuses on CNS disorders with limited current treatment options.
AXS-05, an NMDA receptor antagonist, targets major depressive disorder and treatment-resistant depression.
Axsome's balanced portfolio includes both clinical and research stage products.

Upsides

FDA's fast-tracking of CNS treatments could expedite Axsome's drug approvals.
Increased investment in CNS R&D drives innovation, benefiting Axsome's pipeline.
Growing personalized medicine trend offers Axsome opportunities for tailored therapies.

Land your dream remote job 3x faster with AI